LEADER 04510nam 2201009z- 450 001 9910580213903321 005 20231214133523.0 035 $a(CKB)5690000000011949 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/87533 035 $a(EXLCZ)995690000000011949 100 $a20202207d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNeurotransmitter-Related Molecular Modeling Studies 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (188 p.) 311 $a3-0365-4277-9 311 $a3-0365-4278-7 330 $aThis book focuses of the neurotransmission phenomenon. By definition, neurotransmitters are chemicals that enable communication, i.e., the flow of nerve impulses between nerve cells or between nerve cells and muscles and glands. Recently, one can distinguish excitatory and inhibitory mediators, both of which are endo?exogenous compounds that control the function of the whole organism. From a chemical point of view, neurotransmitters belong to many different structural groups, such as amino acids (such as glycine), peptides (such as substance P, somatostatin), monoamines (such as noradrenaline or dopamine), purine derivatives (such as adenosine), gases (such as nitrogen, NO, carbon monoxide CO), and acetylcholine. From a medical point of view, disturbances in the concentration of neurotransmitters in the body result in the occurrence of mental disorders and diseases (such as depression, schizophrenia, Parkinson?s disease) and contribute to the occurrence of dementia (including Alzheimer?s disease), among other diseases. However, the problem is much wider. These disorders can lead to a number of cardiovascular diseases and can lead to the development of vascular diseases of the brain as well as in many other organs. Therefore, pharmacological intervention is a therapy that tries to interfere with regulatory processes year after year. Such treatments improve survival, reduce the frequency of readmission, and improve patients' quality of life. 606 $aResearch & information: general$2bicssc 606 $aChemistry$2bicssc 610 $awhite matter hyperintensities 610 $adysautonomia 610 $agenetic polymorphisms 610 $adementia 610 $alevodopa 610 $arenin-angiotensin system 610 $aorthostatic hypotension 610 $areserpine-induced fibromyalgia model 610 $avortioxetine 610 $aropinirole 610 $aserotonin and dopamine in fibromyalgia 610 $amouse 610 $adopamine 610 $aacetylcholine 610 $aglutamate 610 $aBDNF 610 $aserotonin 610 $aneurotransmitters 610 $astatins 610 $aneurodegenerative diseases 610 $astroke 610 $adepression 610 $aandrogenetic alopecia 610 $a3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 610 $amixed dyslipidemia 610 $arisk factors 610 $ahalogenated pyrazolines 610 $amonoamine oxidase inhibitors 610 $akinetics 610 $areversibility 610 $amolecular dynamics 610 $aguanylate cyclase (GC) 610 $achronic heart failure (CHF) 610 $apulmonary arterial hypertension (PAH) 610 $atiagabine 610 $acardiac voltage-gated ion channels 610 $amolecular modeling 610 $aECG study 610 $aSGLT2i 610 $asodium-glucose cotransporter 2 inhibitors 610 $aneuroprotection 610 $aatheroprotection 610 $amTOR 610 $atype 2 diabetes mellitus 610 $acognitive impairment 610 $ainflammation 610 $aoxidative stress 610 $aantibiotics 610 $aneurotoxicity 610 $aadverse drug reaction 610 $aneurotransmission 610 $a5-HT receptors 610 $agastrointestinal tract 615 7$aResearch & information: general 615 7$aChemistry 700 $aNowaczyk$b Alicja$4edt$01332311 702 $aGrze?k$b Grzegorz$4edt 702 $aNowaczyk$b Alicja$4oth 702 $aGrze?k$b Grzegorz$4oth 906 $aBOOK 912 $a9910580213903321 996 $aNeurotransmitter-Related Molecular Modeling Studies$93040814 997 $aUNINA